Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health to $40 from $30 and keeps a Neutral rating on the shares. The analyst updated the company’s model post the earnings report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GH:
- Guardant Health price target raised to $50 from $40 at Citi
- Guardant Health raises FY23 revenue view to $545M-$550M from $535M-$545M
- Guardant Health reports Q2 EPS (67c), consensus ($1.18)
- Guardant Health resolves pending litigation with Illumina
- Guardant360 CDx to receive national reimbursement approval from MHLW